0001104659-23-061967.txt : 20230518 0001104659-23-061967.hdr.sgml : 20230518 20230517174356 ACCESSION NUMBER: 0001104659-23-061967 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230515 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230518 DATE AS OF CHANGE: 20230517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERCEPT PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001270073 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 223868459 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35668 FILM NUMBER: 23933086 BUSINESS ADDRESS: STREET 1: 305 MADISON AVENUE CITY: MORRISTOWN STATE: NJ ZIP: 07960 BUSINESS PHONE: 646-747-1000 MAIL ADDRESS: STREET 1: 305 MADISON AVENUE CITY: MORRISTOWN STATE: NJ ZIP: 07960 FORMER COMPANY: FORMER CONFORMED NAME: INTERCEPT PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031113 8-K 1 tm2316034d1_8k.htm FORM 8-K
0001270073 false 0001270073 2023-05-15 2023-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): May 15, 2023

 

Intercept Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware  001-35668  22-3868459
(State or other jurisdiction  (Commission  (IRS Employer
of incorporation)  File Number)  Identification No.)

 

305 Madison Avenue, Morristown, NJ 07960

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (646) 747-1000

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading
Symbol(s)		 Name of each exchange on which
registered
Common Stock, par value $0.001 per share ICPT Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

  

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

On May 15, 2023, Intercept Pharma Europe Ltd. (“IPEL”), a wholly owned subsidiary of registrant Intercept Pharmaceuticals, Inc. (the “Company”), entered into an Amendment (the “Amendment”) to the Agreement for the Supply of Manufactured Products (the “Supply Agreement”) dated May 5, 2022 between IPEL and Amdipharm Ltd. (“Amdipharm”), an affiliate of Advanz Pharma (together with its affiliates, “Advanz”). In 2022, Advanz bought the Company’s ex-U.S. commercial operations, sublicensed the right to commercialize obeticholic acid (“OCA”) for primary biliary cholangitis (“PBC”) and (if approved) nonalcoholic steatohepatitis (“NASH”) outside of the United States, and contracted with IPEL to supply Amdipharm with OCA tablets for PBC and (if approved) NASH.

 

The Amendment clarifies and elaborates definitions pertaining to OCA products for PBC and NASH, including expected tablet sizes and calculation of demonstrable costs of manufacture, and updates timing and procedures for sale of 25 mg tablets of OCA for NASH from IPEL to Amdipharm.

 

Furthermore, the Amendment provides that Amdipharm and Advanz may not use any product purchased under the Supply Agreement for an early access program, expanded access program, authorization for temporary use program, or similar program (each, an “EAP”), without specific prior written approval by the Company. However, following the execution of the agreement described in Item 8.01 below, Amdipharm may engage in an EAP in France for OCA for NASH without further approval from the Company.

 

The Amendment is attached as Exhibit 10.1 and incorporated herein by reference. This description of the Amendment is not complete, and is qualified by reference to the text of the Amendment.

 

Item 8.01 Other Events.

 

On May 15, 2023, the Company agreed with Advanz affiliates Mercury Pharma Group Limited (“Mercury”) and Advanz Pharma France SAS (“Advanz France”) to settle and have “finally resolved” the responsibility of the Company for the liability of Advanz France to the French government for payback of past amounts received for product sales. Under the Share Purchase Agreement (the “SPA”) dated May 5, 2022 between the Company and Mercury, the Company sold ownership of Advanz France (formerly known as Intercept Pharma France SAS) to Mercury, while the Company retained responsibility to Advanz for the cost of this liability to the French government. Pursuant to clause 14.2 of the SPA, Mercury will pay the Company approximately $74,000, representing the approximate dollar equivalent of the difference of approximately €67,000 between the liability estimated in the SPA (€40,600,000) and the actual liability agreed between the parties (approximately €40,533,000).

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit Number Description
10.1 Amendment to the Agreement for the Supply of Manufactured Products, dated May 15, 2023, between Intercept Pharma Europe Ltd. and Amdipharm Ltd.
104 Cover Page Interactive Data File (embedded as Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INTERCEPT PHARMACEUTICALS, INC.
   
  By: /s/ Rocco Venezia
  Name: Rocco Venezia
  Title: Chief Accounting Officer

 

Date: May 17, 2023

 

 

 

 EX-10.1 2 tm2316034d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

 

Execution Version

 

AMENDMENT TO THE AGREEMENT FOR THE SUPPLY

OF

MANUFACTURED PRODUCTS

 

This Amendment Agreement (“Amendment”) is made the 15th day of May, 2023 (“Amendment Date”) and is an amendment to the Agreement for the Supply of Manufactured Products made on May 5, 2022 (“Original MSA”) by and between INTERCEPT PHARMA EUROPE LTD., a company incorporated and registered in England and Wales with company number 09224395 whose registered office is at One, Glass Wharf, Bristol, BS2 0ZX (“Supplier”) and AMDIPHARM LTD, a company organized and existing under the laws of Ireland, having its registered office at 3, Burlington Road, Dublin 4, Ireland, and having its trading address at Suite 17, Northwood House, Northwood Avenue, Santry, Dublin 9, Ireland (“Purchaser”).

 

NOW, THEREFORE, in consideration of the rights and obligations contained herein, and for other good and valuable consideration, the adequacy of which is hereby acknowledged, the Parties hereby agree as follows:

 

1.             For purposes of this Amendment, the terms defined in the Original MSA have the same meanings when used in this Amendment unless specifically indicated otherwise.

 

2.             Clause 1.1 of the Original MSA is amended by:

 

2.1inserting the following definitions (following the alphabetical nature of the list in clause 1):

 

“Amendment” means the amendment to the Agreement dated as of the Amendment Date.

 

“Amendment Date” means May 15th, 2023.

 

“CEPS Letter” means the letter dated as of the date hereof from Mercury Pharma Group Limited (“MPGL”) and Advanz Pharma France SAS to Intercept Pharmaceuticals, Inc. regarding the resolution and repayment of the liability of the former Intercept Pharma France SAS to the French government relating to historical sales of PBC Product.

 

“EMA” means the European Medicines Agency.

 

“HC” means Health Canada.

 

“Marketing Approval(s)” mean all approvals and permissions (excluding reimbursement approvals) from the Regulatory Authorities in the Territory (as defined in the Sub-License Agreement) (or parts of the Territory) that are necessary for the importation or manufacturing (if applicable) of the Products and their distribution, use, marketing, and sale in the Territory (or parts of the Territory).

 

 

 

 

“MHRA UK” means the Medicines and Healthcare products Regulatory Agency.

 

“PBC Product” means the Products that contain OCA as the sole API for the treatment of PBC, in general expected to be the 5mg and 10mg Products.

 

“PBC” means primary biliary cholangitis.

 

“Initial NASH POs” means both the First NASH PO and the Second NASH PO and “Initial NASH PO” shall mean one or other of them as applicable.

 

“Joint Steering Committee” or “JSC” means the steering committee described in that certain sublicence agreement, dated May 5, 2022, by and between Supplier and MPGL, as amended from time to time.

 

2.2replacing the existing definitions of ‘Demonstrable Costs of Manufacture’, ‘Minimum Order Quantity’, ‘NASH Product’ and ‘Product’ with the following definitions:

 

“Demonstrable Costs of Manufacture” means the costs incurred by the Supplier in procuring the Manufacture of the Products, including, without limitation, third-party manufacturing costs, including (without limitation) costs incurred in purchasing API, tableting, and release testing (estimations of which as at the Effective Date are as set out in Schedule 1); provided, however, notwithstanding any of the foregoing; (i) during the first five (5) years after the Completion, no costs incurred in purchasing API for PBC Products shall be included in the Demonstrable Costs of Manufacture; and (ii) for the First NASH PO only, Demonstrable Costs of Manufacture shall include 50% of the costs incurred for purchasing API and 100% of the costs incurred for tableting and testing unless and until the remaining 50% of costs for API are payable pursuant to clause 4.5.1.

 

“Minimum Order Quantity” means the minimum quantity of a type of Product (being 5mg, 10mg, or 25mg) that may be ordered by the Purchaser in each Purchase Order, being one Batch per Product type.

 

“NASH Products” means the Products that contain OCA as the sole API for the treatment of NASH, in general expected to be the 25mg Products.

 

“Products” means the PBC Products and NASH Products, being the products (i.e. tablets) set out in Schedule 1: Products and, where the context requires, the particular Products ordered by and supplied to the Purchaser.

 

3.             Clause 3 of the Original MSA is amended by inserting the following provision:

 

3.10For the avoidance of doubt, each Forecast provided by the Purchaser shall be split by Product type (i.e. 5mg, 10mg, or 25mg and whether the Product is a PBC Product or NASH Product).

 

2 

 

 

4.             Clause 4 of the Original MSA is amended by:

 

4.1inserting a new sub-clause 4.5 as follows:

 

4.5Notwithstanding any conflicting provision in this Agreement or elsewhere:

 

4.5.1The initial Purchase Order placed by Purchaser to Supplier for 25 mg NASH Product (“First NASH PO”) shall: (a) be submitted by Purchaser to Supplier within 90 calendar days following the Amendment Date, (b) be for one Batch only, (c) subject to compliance with clause 4.4 and this clause 4.5.1, be immediately accepted by the Supplier on receipt of payment in full and cleared funds of the amount invoiced by the Supplier in accordance with clause 12.6, at which point the Purchase Order shall become binding on the parties, and (d) be made available for delivery to Purchaser within 180 calendar days from the date the Supplier was deemed to have accepted the First NASH PO in accordance with this clause.

 

For the First NASH PO, 50% of the costs incurred for purchasing API and 100% of the costs incurred for tableting and testing shall be paid upfront as provided herein. The remaining 50% of the costs for API shall be payable if the Purchaser obtains Marketing Approval(s) from at least one of EMA, HC, or MHRA UK. If payable, such costs shall be paid promptly following such Marketing Approval. However, by December 31, 2024, Purchaser shall pay Supplier the remaining 50% of costs for API if no EMA, HC, or MHRA UK Marketing Approvals have been obtained by December 31, 2024, but also none of EMA, HC, and MHRA UK have yet rejected the NASH Product.

 

4.5.2The second Purchase Order placed by Purchaser to Supplier for 25 mg NASH Product (“Second NASH PO”) shall, notwithstanding any prior Forecast submitted by the Purchaser to the Supplier: (a) be submitted by Purchaser to Supplier within 90 calendar days following receipt of all of the necessary Regulatory Approvals necessary to sell, market and distribute the NASH Product in the United States market, (b) be for up to two (2) Batches only, (c) strictly subject to compliance with clause 4.4 and this clause 4.5.2, be immediately accepted by the Supplier on receipt of payment in full and cleared funds of the amount invoiced by the Supplier in accordance with clause 12.6, at which point the Purchase Order shall become binding on the parties, and (d) be made available for delivery to Purchaser within 180 calendar days from the date the Supplier was deemed to have accepted the Second NASH PO in accordance with this clause.

 

3 

 

 

5              Clause 5 is amended by inserting the following new clause 5.13:

 

5.13        Notwithstanding the last sentence of clause 5.10, the Purchaser shall not, and shall direct its Group Companies not to, and represents and warrants that its Group Companies shall not, use any Products purchased under this Agreement for or in connection with any early access programs, expanded access programs, authorisation for temporary use programs, or similar ("EAPs"), without the specific prior written approval of the Supplier; provided, however, that notwithstanding any of the foregoing, following the execution of the Amendment and the CEPS Letter: (i) the Purchaser may engage in the Early Access Program (Accès Précoce) program in France (the “France EAP”) in its discretion, and Purchaser’s participation in such program shall not require the Supplier’s or its Group Companies’ or the JSC’s further approval or consent; and (ii) Supplier shall supply the Product ordered by Purchaser for use with the France EAP pursuant to the provisions elsewhere herein.

 

6Clause 12 of the Original MSA shall be amended by inserting the following clauses:

 

12.6       Clauses 12.1 and 12.2 shall not apply to the Initial NASH POs. Instead, the Supplier shall invoice in respect of each Initial NASH PO within five (5) days of its receipt of each Initial NASH PO and the Purchaser shall pay such invoices immediately.

 

12.7       For the avoidance of doubt and notwithstanding anything to the contrary in this Agreement, except as specifically provided in clause 1.1 ‘Demonstrable Costs of Manufacture’, the purchase of Products prior to Regulatory Approval shall be entirely at the Purchaser’s risk. The Purchaser shall be obliged to pay the invoices raised in accordance with this Agreement notwithstanding any action by a Regulatory Authority, including any requirement for changes to Product specification after the point at which the Purchaser submits a Purchase Order to the Supplier.

 

7              For the avoidance of doubt, clause 16.7 of the Original MSA (and in particular clause 16.7.5 of the Original MSA) shall continue to apply to the arrangements as modified by this Amendment and the supply of all Products, including NASH Products.

 

8              Schedule 1 of the Original MSA is amended by:

 

7.1deleting the following paragraph:

“***Supply of NASH Product 25mg tablets only available following Regulatory Approval of the NASH Product in the Territory (as defined in the Sub-License Agreement).”

 

7.2adding at the end of the double asterisks paragraph the following:

 

“For the avoidance of doubt, other than as specifically provided herein, nothing shall prevent the Supplier charging the Purchaser its actual Demonstrable Costs of Manufacture incurred from time to time, in accordance with the terms of this Agreement.”

 

4 

 

 

8              Except as expressly amended by this Amendment, the Original MSA shall remain in full force and effect as the same was in effect immediately prior to the date of this Amendment.

 

9              To the extent of any conflict between the terms of the Original MSA and this Amendment, the terms of this Amendment will prevail.

 

10            This Amendment and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation is governed by and construed in accordance with, the law of England and Wales.

 

11            Clause 27 of the Original MSA shall apply to this Amendment as if set out in full within this Amendment. Subject to clause 27 of the Original MSA, as incorporated into this Amendment, each party irrevocably agrees that the courts of England and Wales shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with this Amendment or its subject matter or formation.

 

 

[The remainder of this page is intentionally left blank. Signature page follows.]

 

5 

 

 

IN WITNESS WHEREOF, the Parties have executed this Amendment effective as of the date first written above by their respective officers thereunto duly authorized.

 

For an on behalf of INTERCEPT PHARMA EUROPE LIMITED

 

/s/ Stephanie Kenyon  
by: Stephanie Kenyon  
  Sr. Director  

 

For an on behalf of AMDIPHARM LIMITED

 

/s/ Andreas Stickler  
by: Andreas Stickler  
  Director  

 

6 

 

 EX-101.SCH 3 icpt-20230515.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 icpt-20230515_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 icpt-20230515_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover
May 15, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 15, 2023
Entity File Number 001-35668
Entity Registrant Name Intercept Pharmaceuticals, Inc.
Entity Central Index Key 0001270073
Entity Tax Identification Number 22-3868459
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 305 Madison Avenue
Entity Address, City or Town Morristown
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07960
City Area Code 646
Local Phone Number 747-1000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ICPT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm2316034d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001270073 2023-05-15 2023-05-15 iso4217:USD shares iso4217:USD shares 0001270073 false 8-K 2023-05-15 Intercept Pharmaceuticals, Inc. DE 001-35668 22-3868459 305 Madison Avenue Morristown NJ 07960 646 747-1000 false false false false Common Stock, par value $0.001 per share ICPT NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://interceptpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2316034d1_8k.htm icpt-20230515.xsd icpt-20230515_lab.xml icpt-20230515_pre.xml tm2316034d1_ex10-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2316034d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2021q4": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "tm2316034d1_8k.htm" ] }, "labelLink": { "local": [ "icpt-20230515_lab.xml" ] }, "presentationLink": { "local": [ "icpt-20230515_pre.xml" ] }, "schema": { "local": [ "icpt-20230515.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "icpt", "nsuri": "http://interceptpharma.com/20230515", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2316034d1_8k.htm", "contextRef": "From2023-05-15to2023-05-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://interceptpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2316034d1_8k.htm", "contextRef": "From2023-05-15to2023-05-15", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://interceptpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001104659-23-061967-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-061967-xbrl.zip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